17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Myotonic dystrophy type 1 (DM1) Cell culture and mouse studies suggest inhibiting miR-23b and miR-218 could help treat DM1. In myoblast cells from a DM1 patient, miR-23b and miR-218 antagomirs decreased disease-associated splicing defects...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting FST could help treat insulin resistance and glucose intolerance. In a genetic mouse model of glucose intolerance and hyper insulinemia, liver-specific knockdown of FST decreased hepatic glucose production, serum insulin...
23:27 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Studies in mice suggest dual inhibition of IRS1 and IRS2 could help treat KRAS-mutant NSCLC. In a mouse model of KRAS-mutant NSCLC, lung-specific dual knockout of IRS1 and IRS2 increased...
19:07 , Apr 27, 2018 |  BC Extra  |  Company News

Sanofi's Dupixent misses sales estimates, Regeneron slips

Sanofi (Euronext:SAN; NYSE:SNY) reported 1Q18 earnings, including sales of atopic dermatitis drug Dupixent dupilumab that missed estimates. The company's partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slid $10.92 to $313.05 on the news Friday, shedding nearly $1.2 billion...
18:57 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

ArmaGen Inc. (Calabasas, Calif.) reported data from stage 2 of the Phase II portion of a Phase I/II trial in patients ages two and older with severe mucopolysaccharidosis I (MPS I, Hurler syndrome) showing that...
18:53 , Oct 27, 2017 |  BC Week In Review  |  Company News

Biocon, JDRF in deal for insulin tregopil study

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) and JDRF (New York, N.Y.) partnered to conduct a two-part, open-label Phase I study of insulin tregopil to treat Type I diabetes. The trial's first part will determine the optimal dosing...
18:02 , Sep 1, 2017 |  BC Week In Review  |  Company News

Xoma, Novartis partner for IL-1 beta mAbs and related IP

Xoma Corp. (NASDAQ:XOMA) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab (XOMA 052). The company also granted Novartis a non-exclusive license to IP covering IL-1 beta-targeting antibodies to...
21:34 , Aug 25, 2017 |  BC Extra  |  Company News

Xoma gains on Novartis IL-1 beta mAb deals

Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN) worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab (XOMA 052). The company also granted Novartis a non-exclusive license...
06:12 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous doses of 0.15 U/kg BioChaperone Lispro vs. 0.15 U/kg Fiasp (faster-acting insulin aspart, NN1218) or 0.15 U/kg Novolog...
20:13 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Novo Nordisk reports additional Phase III DEVOTE data of Tresiba on CV outcomes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) reported additional data from the Phase III DEVOTE trial in 7,637 Type II diabetics at high risk of cardiovascular (CV) disease showing that once-daily subcutaneous Tresiba insulin degludec (NN1250) plus...